TD Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

TD Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-68,046	Closed	-$244K	–	1301
2026 Q1	$244K	Sell	68,046 -34,492	-34%	-$137K	﹤0.01%	1216
2025 Q4	$360K	Hold	102,538	–	–	﹤0.01%	1192
2025 Q3	$334K	Sell	102,538 -72,372	-41%	-$228K	﹤0.01%	1197
2025 Q2	$429K	Buy	174,910 +12,200	+7%	+$61.8K	﹤0.01%	1144
2025 Q1	$1.09M	Sell	162,710 -15,744	-9%	-$156K	﹤0.01%	1061
2024 Q4	$2.24M	Buy	178,454 +844	+0.5%	+$12.7K	﹤0.01%	977
2024 Q3	$3.28M	Sell	177,610 -554	-0.3%	-$11.3K	﹤0.01%	890
2024 Q2	$3.84M	Buy	178,164 +23,000	+15%	+$528K	﹤0.01%	824
2024 Q1	$4.18M	Buy	155,164 +300	+0.2%	+$8.52K	﹤0.01%	813
2023 Q4	$4.64M	Buy	154,864 +42,834	+38%	+$945K	﹤0.01%	780
2023 Q3	$2.3M	Buy	112,030 +56,015	+100%	+$1.02M	﹤0.01%	921
2023 Q2	$1.11M	Buy	56,015 +16,100	+40%	+$325K	﹤0.01%	1104
2023 Q1	$684K	Sell	39,915 -2,300	-5%	-$45K	﹤0.01%	1212
2022 Q4	$826K	Buy	42,215 +9,063	+27%	+$167K	﹤0.01%	1178
2022 Q3	$465K	Sell	33,152 -33,031	-50%	-$515K	﹤0.01%	1307
2022 Q2	$911K	Hold	66,183	–	–	﹤0.01%	1199
2022 Q1	$1.05M	Hold	66,183	–	–	﹤0.01%	1225
2021 Q4	$1.45M	Sell	66,183 -16,700	-20%	-$456K	﹤0.01%	1207
2021 Q3	$2.48M	Hold	82,883	–	–	﹤0.01%	1025
2021 Q2	$2.97M	Sell	82,883 -6,050	-7%	-$263K	﹤0.01%	968
2021 Q1	$3.95M	Buy	88,933 +9,509	+12%	+$522K	﹤0.01%	896
2020 Q4	$4.36M	Buy	79,424 +17,361	+28%	+$633K	0.01%	828
2020 Q3	$1.42M	Buy	62,063 +22,858	+58%	+$563K	﹤0.01%	998
2020 Q2	$821K	Hold	39,205	–	–	﹤0.01%	1106
2020 Q1	$547K	Sell	39,205 -9,300	-19%	-$184K	﹤0.01%	1159
2019 Q4	$1.1M	Buy	48,505 +11,173	+30%	+$187K	﹤0.01%	1069
2019 Q3	$435K	Buy	37,332 +8,189	+28%	+$102K	﹤0.01%	1197
2019 Q2	$437K	Buy	29,143 +5,180	+22%	+$90.4K	﹤0.01%	1198
2019 Q1	$420K	Sell	23,963 -1,300	-5%	-$20.5K	﹤0.01%	1217
2018 Q4	$374K	Buy	25,263 +4,768	+23%	+$79.2K	﹤0.01%	1277
2018 Q3	$505K	Hold	20,495	–	–	﹤0.01%	1290
2018 Q2	$402K	Buy	20,495 +300	+1%	+$5.67K	﹤0.01%	1307
2018 Q1	$379K	Buy	+20,195	New	+$329K	﹤0.01%	1248
2017 Q1	–	Sell	-10,300	Closed	-$251K	–	1415
2016 Q4	$251K	Sell	10,300 -125	-1%	-$3.57K	﹤0.01%	1313
2016 Q3	$395K	Buy	10,425 +2,475	+31%	+$77.8K	﹤0.01%	1240
2016 Q2	$237K	Sell	7,950 -100	-1%	-$3.52K	﹤0.01%	1297
2016 Q1	$238K	Sell	8,050 -250	-3%	-$7.5K	﹤0.01%	1282
2015 Q4	$376K	Sell	8,300 -2,125	-20%	-$92.6K	﹤0.01%	1176
2015 Q3	$392K	Buy	+10,425	New	+$479K	﹤0.01%	1136

Other funds holding RCKT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Asset Management's RCKT Position: Q2 2026 in Review

TD Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 68,046 shares — an estimated $244K sold.

TD Asset Management first reported a position in RCKT in Q3 2015 and held it in 39 quarters. The position peaked at $4.64M in Q4 2023. 116 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

TD Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
TD Asset Management sold 68,046 Rocket Pharmaceuticals shares in Q2 2026, an estimated $244K.
TD Asset Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 39 quarters.
TD Asset Management's Rocket Pharmaceuticals position peaked at $4.64M in Q4 2023.
116 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.